GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » Equity-to-Asset

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Equity-to-Asset

: 0.96 (As of Sep. 2023)
View and export this data going back to 2021. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Theseus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $224.52 Mil. Theseus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $234.63 Mil.

The historical rank and industry rank for Theseus Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

THRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.59   Med: 0.95   Max: 0.98
Current: 0.96

During the past 4 years, the highest Equity to Asset Ratio of Theseus Pharmaceuticals was 0.98. The lowest was -6.59. And the median was 0.95.

THRX's Equity-to-Asset is ranked better than
96.36% of 1567 companies
in the Biotechnology industry
Industry Median: 0.67 vs THRX: 0.96

Theseus Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Theseus Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
-6.59 -3.98 0.98 0.93

Theseus Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.93 0.96 0.96 0.96

Competitive Comparison

For the Biotechnology subindustry, Theseus Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theseus Pharmaceuticals Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's Equity-to-Asset falls into.



Theseus Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Theseus Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=207.615/222.447
=

Theseus Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=224.522/234.627
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theseus Pharmaceuticals  (NAS:THRX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Theseus Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Cambridge, MA, USA, 02142
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson director, officer: President and CEO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein director 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare officer: See Remarks 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022